1414 ET - Life sciences and diagnostic tools companies are primed for surprisingly good 1Qs amid positive pre-announcements from Pacific Biosciences of California, Qiagen NV and Bruker, but don't fall for the initial positive news, Bank of America analysts say in a research note. "We wouldn't overreact to these initial prints," the analysts say, adding headwinds from National Institutes of Health budget cuts, tariffs and a trade war with China only materialized recently, giving companies one to two months of regular business activity in the 1Q. The real risk, then, lies in 2Q/3Q and the rest of FY25, the analysts say. They expect softer commentary particularly from academic and government exposed companies like Illumina, 10x Genomics and others, while diagnostics companies are likely a safer bet, they say. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
April 14, 2025 14:14 ET (18:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。